BHCM
MBX

Brevan Howard Capital Management’s MBX Biosciences MBX Stock Holding History

Brevan Howard Capital Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$475K Buy
+8,602
New +$300K ﹤0.01% 1477
2026
Q1 		– Sell
-25,663
Closed -$809K – 2571
2025
Q4 		$809K Buy
+25,663
New +$623K 0.01% 868

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Brevan Howard Capital Management's MBX Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in MBX Biosciences (MBX) in Q2 2026: 8,602 shares worth $475K. The stake represents ﹤0.01% of the portfolio and ranks #1477 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in MBX as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in MBX in Q4 2025 and has held it in 2 quarters since. The position peaked at $809K in Q4 2025. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Brevan Howard Capital Management held 8,602 shares of MBX Biosciences worth $475K as of Q2 2026.
  • MBX Biosciences was a new Brevan Howard Capital Management position in Q2 2026.
  • MBX Biosciences made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1477 holding.
  • Brevan Howard Capital Management first reported a position in MBX Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Brevan Howard Capital Management's MBX Biosciences position peaked at $809K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.